AstraZeneca PLC (OTCMKTS:AZNCF) Short Interest Down 41.9% in June

AstraZeneca PLC (OTCMKTS:AZNCF) saw a large drop in short interest in June. As of June 15th, there was short interest totalling 12,200 shares, a drop of 41.9% from the May 31st total of 21,000 shares. Based on an average daily trading volume, of 3,600 shares, the short-interest ratio is presently 3.4 days.

AstraZeneca Stock Performance

Shares of OTCMKTS AZNCF traded down $2.37 during trading hours on Friday, reaching $156.27. 1,001 shares of the stock traded hands, compared to its average volume of 3,410. AstraZeneca has a 52-week low of $118.16 and a 52-week high of $162.00. The company’s 50-day simple moving average is $154.02 and its two-hundred day simple moving average is $139.86.

Hedge Funds Weigh In On AstraZeneca

A hedge fund recently bought a new stake in AstraZeneca stock. Kennedy Capital Management LLC purchased a new position in AstraZeneca PLC (OTCMKTS:AZNCF) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 37,554 shares of the company’s stock, valued at approximately $5,068,000. 40.87% of the stock is currently owned by institutional investors and hedge funds.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.